Strs Ohio Has $10,701,000 Stake in Zimmer Biomet Holdings Inc. (ZBH)
Strs Ohio reduced its position in Zimmer Biomet Holdings Inc. (NYSE:ZBH) by 66.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,895 shares of the company’s stock after selling 177,487 shares during the period. Strs Ohio’s holdings in Zimmer Biomet Holdings were worth $10,701,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the company. TIAA CREF Investment Management LLC raised its position in Zimmer Biomet Holdings by 122.1% in the first quarter. TIAA CREF Investment Management LLC now owns 1,081,566 shares of the company’s stock worth $115,327,000 after buying an additional 594,588 shares during the last quarter. NN Investment Partners Holdings N.V. acquired a new stake in shares of Zimmer Biomet Holdings during the first quarter worth about $42,048,000. Atalanta Sosnoff Capital LLC acquired a new stake in shares of Zimmer Biomet Holdings during the second quarter worth about $42,984,000. Teachers Advisors Inc. increased its stake in shares of Zimmer Biomet Holdings by 100.5% in the first quarter. Teachers Advisors Inc. now owns 704,953 shares of the company’s stock worth $75,169,000 after buying an additional 353,346 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its stake in shares of Zimmer Biomet Holdings by 36.3% in the first quarter. Adage Capital Partners GP L.L.C. now owns 894,005 shares of the company’s stock worth $95,328,000 after buying an additional 238,107 shares during the period. 88.30% of the stock is owned by hedge funds and other institutional investors.
Zimmer Biomet Holdings Inc. (NYSE:ZBH) traded up 1.71% during trading on Friday, hitting $130.02. 1,391,322 shares of the stock traded hands. The firm has a 50-day moving average price of $127.88 and a 200 day moving average price of $120.44. The firm has a market cap of $26.01 billion, a PE ratio of 118.74 and a beta of 0.95. Zimmer Biomet Holdings Inc. has a 12 month low of $88.27 and a 12 month high of $133.19.
Zimmer Biomet Holdings (NYSE:ZBH) last announced its earnings results on Thursday, July 28th. The company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.97 by $0.05. The firm had revenue of $1.93 billion for the quarter, compared to analysts’ expectations of $1.90 billion. Zimmer Biomet Holdings had a net margin of 1.68% and a return on equity of 16.12%. The business’s revenue was up 65.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.58 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings Inc. will post $7.97 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, September 23rd will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date is Wednesday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is currently 157.38%.
ZBH has been the topic of a number of recent analyst reports. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $125.00 price objective on shares of Zimmer Biomet Holdings in a research report on Tuesday, June 21st. Jefferies Group reiterated a “buy” rating and issued a $150.00 price objective on shares of Zimmer Biomet Holdings in a research report on Monday, August 8th. Argus reiterated a “buy” rating and issued a $140.00 price objective on shares of Zimmer Biomet Holdings in a research report on Thursday, September 22nd. Guggenheim initiated coverage on Zimmer Biomet Holdings in a research report on Wednesday, June 8th. They issued a “neutral” rating on the stock. Finally, Barclays PLC increased their price objective on Zimmer Biomet Holdings from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 23rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-two have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $132.36.
In related news, insider David A. Jr. Nolan sold 25,255 shares of the stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $130.77, for a total value of $3,302,596.35. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Tony W. Collins sold 1,287 shares of the stock in a transaction dated Friday, August 12th. The stock was sold at an average price of $129.16, for a total transaction of $166,228.92. The disclosure for this sale can be found here. 1.22% of the stock is currently owned by corporate insiders.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.